logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
FDMT
4D Molecular Therapeutics, Inc.
14.11
2 x 10.44
1 x 14.14
bid
ask
-
0.56
3.82%
2 @ 05:56 PM
13.80 -0.31 (2.20%)
Ytd88.13%
1y129.06%
13.66
day range
14.60
5.97
52 week range
16.93
Open14.49Prev Close14.67Low13.66High14.60Mkt Cap779.50M
Vol1.40MAvg Vol950.60KEPS-2.63P/EN/AForward P/E-1.79
Beta2.73Short Ratio9.86Inst. Own115.21%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-1050-d Avg12.14200-d Avg10.011yr Est42.64

FDMT News

4DMT to Participate in Upcoming Investor Conferences
globenewswire.com
4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

4D Molecular Therapeutics, Inc. $FDMT Stake Boosted by Bank of America Corp DE
defenseworld.net
4D Molecular Therapeutics, Inc. $FDMT Stake Boosted by Bank of America Corp DE

Bank of America Corp DE lifted its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT)

Deutsche Bank AG Invests $9.46 Million in 4D Molecular Therapeutics, Inc. $FDMT
defenseworld.net
Deutsche Bank AG Invests $9.46 Million in 4D Molecular Therapeutics, Inc. $FDMT

Deutsche Bank AG acquired a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) in the secon

4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month High – Time to Buy?
defenseworld.net
4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month High – Time to Buy?

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report)'s share price reached a new 52-week

4DMT Announces New Employment Inducement Grants
globenewswire.com
4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.04 per share in line wit

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
globenewswire.com
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Mil

Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027  4D-150 4
benzinga.com
B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price

B. Riley Securities analyst Mayank Mamtani initiates coverage on 4D Molecular Therapeutics (NASDA

10 Stock Picks to Celebrate 45 Years of Schaeffer's
schaeffersresearch.com
10 Stock Picks to Celebrate 45 Years of Schaeffer's

Subscribers to  Chart of the Week  received this commentary on Sunday, July 26.

4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion Opportunity
seekingalpha.com
4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion Opportunity

4D Molecular Therapeutics, Inc. maintains a Buy rating, driven by advancing 4D-150 gene therapy for

4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win
benzinga.com
4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win

4D Molecular Therapeutics reports positive 2-year Phase 2b data for 4D-150 in wet AMD, showing up to
benzinga.com
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDM
benzinga.com
Reported Saturday, 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction

After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with c

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
globenewswire.com
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

EMERYVILLE, Calif., July 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

4DMT Announces New Employment Inducement Grants
globenewswire.com
4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
globenewswire.com
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Spec

EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

benzinga.com
4D Molecular Therapeutics Completes Enrollment For Its 4FRONT-2 Second Phase 3 Clinical Trial Evalua

4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections4FRONT-2 ove

4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
globenewswire.com
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
globenewswire.com
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD

EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT,

Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?
zacks.com
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?

4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume.

4DMT Announces New Employment Inducement Grants
globenewswire.com
4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com
4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Confe

4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Confe

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com
4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Trans

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Trans

4DMT to Participate in Upcoming Investor Conferences
globenewswire.com
4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT o

4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
seekingalpha.com
4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference

4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference

benzinga.com
4D Molecular Therapeutics Q1 EPS $(1.01) Misses $(0.99) Estimate, Sales $3.047M Miss $5.167M Estimat

4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed

benzinga.com
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDM
benzinga.com
RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35

RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperfo
benzinga.com
UPDATE: 4D Molecular Therapeutics Q4 EPS $0.43 Beats $(0.53) Estimate, Sales $85.090M Beat $32.245M

4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly earnings of $0.43 per share which beat th
benzinga.com
4D Molecular Therapeutics Completes Patient Enrollment In 4FRONT-1 Trial Evaluating 4D-150

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology c

Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings)
benzinga.com
Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings)

BlackBerry, FedEx, Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
benzinga.com
BlackBerry, FedEx, Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
benzinga.com
Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Maintains $26 Price Target

Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a

benzinga.com
4D Molecular Therapeutics Says Interim Data From 4D-710 Phase 1 AEROW Trial For Cystic Fibrosis Lung

Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through

benzinga.com
RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $32

RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperfo
benzinga.com
Barclays Maintains Overweight on 4D Molecular Therapeutics, Lowers Price Target to $33

Barclays analyst Gena Wang maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Overweight an
benzinga.com
Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $26

Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a

benzinga.com
4D Molecular Therapeutics Q3 EPS $(1.01) Misses $(0.98) Estimate, Sales $90.000K Miss $287.857K Esti

4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed

benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
4D Molecular Therapeutics Prices $100M Offering Including 8.4M Common Shares At $10.51 Each And 1.1M

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology co
benzinga.com
4DMT's 4D-150 Demonstrates Durable, Multi-Year Benefit Supporting Its Potential As A Backbone Therap

4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by

benzinga.com
Reported Earlier, 4DMT And Otsuka Pharmaceutical Sign $85M Upfront License Deal With Up To $336M In

4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost

benzinga.com
Beyond The Numbers: 4 Analysts Discuss 4D Molecular Therapeutics Stock
benzinga.com
RBC Capital Reiterates Outperform on 4D Molecular Therapeutics, Maintains $26 Price Target

RBC Capital analyst Lisa Walter reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperf
benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

Jim Cramer: AppLovin Calls For Prudence, This Health Care Stock Is 'Pure Spec'
benzinga.com
Jim Cramer: AppLovin Calls For Prudence, This Health Care Stock Is 'Pure Spec'

Jim Cramer doesn't recommend buying more AppLovin stock. "Let's take a little off the ta
benzinga.com
What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics
benzinga.com
Roth Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $38

Roth Capital analyst Salveen Richter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy
benzinga.com
Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Maintains $25 Price Target

Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a